| __timestamp | Bio-Techne Corporation | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 60716000 | 10811000 |
| Thursday, January 1, 2015 | 119401000 | 33001000 |
| Friday, January 1, 2016 | 140879000 | 64936000 |
| Sunday, January 1, 2017 | 199243000 | 99909000 |
| Monday, January 1, 2018 | 240636000 | 127724000 |
| Tuesday, January 1, 2019 | 264359000 | 161524000 |
| Wednesday, January 1, 2020 | 260583000 | 182933000 |
| Friday, January 1, 2021 | 324951000 | 219982000 |
| Saturday, January 1, 2022 | 372766000 | 278139000 |
| Sunday, January 1, 2023 | 378378000 | 309799000 |
| Monday, January 1, 2024 | 396826000 |
Unleashing insights
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Bio-Techne Corporation and Ultragenyx Pharmaceutical Inc. have been navigating this challenge since 2014. Over the years, Bio-Techne has consistently maintained higher SG&A expenses, peaking at approximately $397 million in 2024. In contrast, Ultragenyx's expenses reached around $310 million by 2023, showing a steady increase.
Bio-Techne's SG&A costs grew by over 550% from 2014 to 2024, while Ultragenyx saw a staggering increase of nearly 2,800% from 2014 to 2023. This dramatic rise in Ultragenyx's expenses highlights its aggressive expansion strategy. However, the absence of data for Ultragenyx in 2024 leaves room for speculation on its future trajectory. As these companies continue to evolve, their ability to optimize SG&A costs will be pivotal in determining their market success.
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Bio-Techne Corporation
Comparing SG&A Expenses: BeiGene, Ltd. vs Ultragenyx Pharmaceutical Inc. Trends and Insights
United Therapeutics Corporation vs Ultragenyx Pharmaceutical Inc.: SG&A Expense Trends
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: SG&A Expense Trends
Comparing SG&A Expenses: Insmed Incorporated vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Bio-Techne Corporation vs Rhythm Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Bausch Health Companies Inc.
Breaking Down SG&A Expenses: Bio-Techne Corporation vs Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Taro Pharmaceutical Industries Ltd.
Selling, General, and Administrative Costs: Bio-Techne Corporation vs Evotec SE
Ultragenyx Pharmaceutical Inc. vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends